Avidity Biosciences, Inc. (RNA)
NEUTRALFundamental
36
Precio
$13.85
Capitalización Bursátil
$226M
Parte 1 · Cuánto vale la empresa
Resumen
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$36M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-448M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
-
Patrimonio Neto Total
$1.69B
Pasivo Total
$269M
Ratio de Liquidez
8.73
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$25.00
Precio Actual
$13.85
Margen de Seguridad
+44.6%
Rango de Valor Justo
$23.75 - $26.25
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-40.5%
Ratio P/B
1.09
P/FCF
-
Margen Bruto
-
ROIC
-153.3%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-153.3%
WACC
10.2%
ROIC − WACC
-163.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (6)
- P/B Ratio 1.09
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 86% Buy
- Earnings Surprise avg 8.5%
Fallido (9)
- EPS shows upward trend
- ROIC -153.3%
- Operating Margin -1343.1%
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -40.3%
- Share Dilution 88.9%
- Net Margin Trend -3650.4% vs -2219.9%
- Piotroski F-Score 3/9
No disponible (12)
- Historical price data insufficient
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Ms. Kathleen P. Gallagher | President, CEO & Director | 44 |
| Mr. Brendan Winslow | Chief Financial Officer | 37 |
| Dr. Husam Younis Ph.D., Pharm.D. | Chief Scientific Officer | 51 |
| Ms. Stephanie Kenney | Chief Corporate Affairs Officer | 47 |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer | 58 |
| Ms. Rocio Martin Hoyos | Chief Strategy Officer | 42 |
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for RNA, sourced from Markets Gazette.